NOVAVAX INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
NOVAVAX INC (NVAX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2025-02-27
- NOVAVAX INC effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 0.00%.
- NOVAVAX INC effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 0.00%.
- NOVAVAX INC effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -1.00%.
- NOVAVAX INC effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -2.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | 0.00% 10-K · filed 2025-02-27 | |
| 2023-12-31 | 0.00% 10-K · filed 2025-02-27 | |
| 2022-12-31 | -1.00% 10-K · filed 2025-02-27 | |
| 2021-12-31 | -2.00% 10-K · filed 2024-02-28 | |
| 2020-12-31 | -4.00% 10-K · filed 2023-02-28 | 4.00% 10-K · filed 2021-03-01 |
| 2019-12-31 | 0.00% 10-K · filed 2022-03-01 | |
| 2018-12-31 | 0.00% 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |